RNA, U6 small nuclear 519, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-519P profile across patient tissues and cancer cell-line models. RNU6-519P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RNU6-519P is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, RNU6-519P RNA expression shows 7,438 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, STAD, and GBM as cancer lineages where RNU6-519P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-519P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-519P survival associations across molecular data types. RNU6-519P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-519P RNA expression–survival associations across cancer types. High RNU6-519P expression shows unfavorable associations in KICH, ACC, DLBC, KIRC, UVM and LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RNU6-519P RNA expression.
This table summarizes RNU6-519P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-519P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-519P shows higher tumor expression in STAD, BRCA, LUSC, THCA, HNSC and LIHC. The STAD box plot shows higher RNU6-519P RNA expression in tumor versus normal tissue (log2 FC = +0.620, t-test p = .004).
This table shows molecular features associated with RNU6-519P in patient tissues and cancer cell lines. In patient samples, RNU6-519P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
